InspireMD(US:NSPR)2026-03-18 13:32Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $3.1 million, a 62% increase from $1.9 million in Q4 2024, driven by the U.S. launch of CGuard Prime and increased international market penetration [10] - U.S. revenue for Q4 was $866,000, representing a 74% sequential growth compared to Q3 [10] - International revenue for Q4 was $2.3 million, reflecting a 17% growth compared to $1.9 million in Q4 2024 [10] - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $469,000 or 24.1% of revenue in Q4 2024, primarily due to a favorable shift in revenue mix towards U.S. sales [11] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million or $0.19 per share in Q4 2024 [13] Business Line Data and Key Metrics Changes - The CGuard Prime stent platform has been launched in the U.S., with over 500 cases completed and approvals gained in prominent Integrated Delivery Networks (IDNs) [6] - The company has built a U.S. commercial team of over 30 people, focusing on operational expansion and increasing manufacturing capacity [5] Market Data and Key Metrics Changes - The company is focusing on expanding its market presence in the U.S. and international markets, with a strategy to dominate the carotid stenting space [4] - The anticipated FDA approval for TCAR indications is expected to boost market opportunities significantly [8] Company Strategy and Development Direction - The company aims to achieve market leadership through a stent-first strategy, focusing on operational excellence and customer support [4] - Plans include expanding the clinical pipeline and advancing indications for CGuard, with multiple programs and studies underway [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of U.S. sales and anticipates continued progress in 2026, with revenue expected to be between $13 million and $15 million, reflecting a growth of approximately 45%-65% over 2025 [15] - The company is committed to continuous improvement and exceeding customer expectations, with plans to introduce enhancements to the delivery system in Q4 2026 [26] Other Important Information - Cash and cash equivalents and marketable securities were $54.2 million as of December 31, 2025, compared to $34.6 million at the end of the previous year [14] - The company has two remaining milestone-based tranches from a private placement, each providing gross proceeds of $17.9 million if fully exercised [14] Q&A Session Summary Question: Guidance for FY 2026 - Management expects moderate growth in OUS sales and acceleration in U.S. growth in the second half of 2026 due to anticipated TCAR indication and enhanced clinical performance [19][20] Question: Account Standpoint in the U.S. - Cases have been performed in roughly 80 centers, with over 200 centers in the pipeline for VAC and evaluation stages [23] Question: Next Generation Delivery System - The next generation delivery system is targeted for Q4 2026, with minor regulatory changes expected to go through a 30-day FDA review [26] Question: Timing for CGUARDIANS II Data - CGUARDIANS II data will be first revealed at the Charing Cross Symposium in April, likely as an interim cut [30] Question: Account Adoption and Productivity Metrics - A growing number of physicians are using CGuard as their everyday stent, with an average of 15-20 cases per physician per year [35]